MoonLake's nanobody delivers strong phase 3 results in psoriatic arthritis
TL;DR
MoonLake Immunotherapeutics reported positive topline phase 3 IZAR-1 data for biologic‑naïve psoriatic arthritis patients treated with sonelokimab, with week‑16 endpoints meeting across ACR50 (42.1%), ACR20 (66.5%), minimal disease activity (41.2%), and PASI90 in patients with skin involvement (61%), though there is no active comparator arm and topline results will be followed by blinded analyses with full data due in H1 2027; IZAR-2 and other IL-17 nanobody programs are ongoing.
Topics:businesshealth#health#moonlake-immunotherapeutics#nanobody#phase-3-trial#psoriatic-arthritis#sonelokimab
- MoonLake’s nanobody boosts all clinical endpoints in phase 3 psoriatic arthritis trial Fierce Biotech
- MoonLake Immunotherapeutics Announces Q2 2026 Financial Results with Increased Net Loss and Cash Reserves Kalkine Media
- MoonLake Immunotherapeutics (NASDAQ:MLTX) Releases Earnings Results, Beats Estimates By $0.08 EPS MarketBeat
- Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial Dermatology Times
- MoonLake's psoriatic arthritis drug meets key goals in late-stage trial marketscreener.com
Want the full story? Read the original reporting
Read on Fierce Biotech